Design, synthesis and biological evaluation of novel tetrahydrothieno [2,3-c]pyridine substitued benzoyl thiourea derivatives as PAK1 inhibitors in triple negative breast cancer.

Dahong Yao, Jian Huang, Jinhui Wang, Zhendan He, Jin Zhang

Open access · goldAbstract read

In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.2field-weighted citation impact, top 50% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

Discovery of a Novel Selective PAK1/HDAC6/HDAC10 Inhibitor ZMF-25 that Induces Mitochondrial Metabolic Breakdown and Autophagy-Related Cell Death in Triple-Negative Breast Cancer.Research (Washington, D.C.) · 2025
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Dahong YaoSchool of Pharmaceutical Sciences, Shenzhen Technology University, Shenzhen, China.

Jian HuangDrug Development Department, Shenzhen Honghui Bio-Pharmaceutical Co. Ltd., Shenzhen, China.

Jinhui WangDrug Development Department, Shenzhen Honghui Bio-Pharmaceutical Co. Ltd., Shenzhen, China.

Zhendan HeSchool of Pharmaceutical Sciences, Shenzhen Technology University, Shenzhen, China.

Jin ZhangSchool of Pharmaceutical Sciences, Shenzhen Technology University, Shenzhen, China.

Shenzhen Technology University · CNSichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The overexpression of P21-activated kinase 1 (PAK1) is associated with poor prognosis in several cancers, which has emerged as a promising drug targets. Based on high-throughput virtual screening strategy, tetrahydrothieno [2,3-c]pyridine scaffold was identified as an initial lead for targeting PAK1. Herein we reported our structure-based optimisation strategy to discover a potent PAK1 inhibitor (

Indexed as

Drug DesignAntineoplastic AgentsCell Cycle CheckpointsCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansModels, MolecularMolecular Structurep21-Activated KinasesProtein Kinase InhibitorsStructure-Activity RelationshipThioureaTriple Negative Breast NeoplasmsAntineoplastic Agentsp21-Activated KinasesPAK1 protein, humanProtein Kinase InhibitorsThioureaanti-proliferationbreast cancercell cycle arrestsHigh-throughput virtual screeningPAK1 inhibitor

Identifiers

PMID32752894

DOI10.1080/14756366.2020.1797710

PMCPMC7470115

OpenAlexW3047320553

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.